Stockreport

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer [Yahoo! Finance]

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF historical data of 14.4 months in TRODELVY ® (sacituzumab govitecan-hziy) in similar heavily pre-treated patients Survival data in triple negative breast cancer patien [Read more]